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Dear Editor,
Rituximab is an effective and safe monoclonal antibody in
the treatment of CD20+ malignant lymphoma [1]. In
patients with massive pleural effusions or ascites associated
with lymphoma, it remains unclear whether rituximab
should be administered not only by intravenous infusion
but also via the intraperitoneal route [2–4]. We studied the
association of rituximab concentration and disappearance of
lymphoma cells in ascites after intravenous application. The
concentration of rituximab was low 3 h after infusion, but
increased 24 h later. Flow cytometry (FCM) analyses
revealed several CD20+ lymphoma cells at 3 h which com-
pletely disappeared 24 h later. These observations indicated
that rituximab antibody may be resorbed from the circulation
to the peritoneal cavity and may have an anti-tumor role in
ascites. We report a patient who developed massive ascites
due to a follicular lymphoma who was treated with rituximab.
A 40-year-old male presented with generalized lymph-
adenopathy in 1999. Pathology of the lymph node revealed
a grade-2 follicular B cell lymphoma with the chromosomal
abnormality t(14;18). He received combination chemother-
apy with cyclophosphamide, doxorubicin, vincristine, and
prednisone (CHOP). After three cycles of CHOP, his symp-
toms promptly resolved. He discontinued hospital visits from
2001 onwards.
This patient presented again to our hospital with gener-
alized lymphadenopathy, abdominal discomfort, and mas-
sive ascites in 2008 (Fig. 1a). Biopsy of the left inguinal
lymph node showed regrowth of a CD20+ grade-2 follicular
lymphoma. A bone marrow specimen exhibited several
atypical lymphocytes with t(14;18) by fluorescence in situ
hybridization (FISH). Aspiration of ascites demonstrated
CD20+ B cells and CD3+ T cells by FCM. FISH analyses
showed t(14;18) cells (16%) in ascites. His symptoms (in
particular, abdominal discomfort due to ascites) persisted
despite the first cycle of rituximab plus CHOP (R-CHOP).
We supposed that the concentration of rituximab in ascites
by intravenous infusion was not sufficient to elicit an effect.
Therefore, upon secondary therapy, we administered only
rituximab without CHOP by intravenous infusion to examine
the relationship between rituximab concentration and the dis-
appearance of lymphoma cells in ascites. Concentrations of
rituximab in ascites and serum were 0.8 and 98.1 μg/mL,
respectively, 3 h after infusion, and 3.3 and 21.7 μg/mL
24 h later. Massive ascites was resolved after 3 days of
infusion (Fig. 1b). FCM analyses demonstrated that CD20+
lymphoma cells (22.4%) in ascites at 3 h (Fig. 1c) completely
disappeared 24 h later (Fig. 1d). The patient received six
cycles of R-CHOP and was doing well.
A few reports have suggested that lymphoma with mas-
sive effusions or ascites demands local therapies such as
intraperitoneal administration of rituximab as well as sys-
temic chemotherapy [2–4]. Unfortunately, those studies did
not measure the level of rituximab in ascites, effusions, or
serum before and after local instillation. Thus, whether local
(not systemic) administration is required for the manage-
ment of ascites or effusions is not known. The mechanism of
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action of rituximab is incompletely understood. However,
rituximab is thought to induce cell destruction, including
apoptosis, complement-dependent cytotoxicity (CDCC), and
antibody-dependent cellular cytotoxicity (ADCC) [5]. In in
vitro studies, rituximab induced direct cytotoxicity against the
RAJI CD20+-expressing lymphoma cell line at >0.1 μg/mL
[5]. That report showed that, after 4-h incubation in human
serum, direct cytotoxicity was not evident, but after 3 days of
culture, remarkable combined direct cytotoxicity and CDCC
was induced [5]. In our case, we identified a rituximab
concentration in ascites >0.1 μg/mL 3 and 24 h later only
by intravenous administration. The remaining CD20+ lym-
phoma cells (22.4%) in ascites at 3 h completely disappeared
24 h later. These findings suggested that rituximab in ascites
may mediate not only direct cytotoxicity against lymphoma
cells, but also CDCC or ADCC induced by serum and
several CD3+ cells in ascites as effector cells. The efficacy
of rituximab may be dependent upon the relative ratio of
effector cells (CD3+ lymphocytes) to target cells (CD20+
lymphoma cells) in ascites. However, the exact mechanism
of cytotoxicity remains unclear. The pharmacokinetics and
efficacy of rituximab should be investigated in a larger study
population.
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Fig. 1 CT of the abdomen
before and after intravenous
instillation of rituximab. a
Massive ascites before infusion.
b Three days after infusion,
ascites was resolved. Changes
in lymphoma cells double-
positive for CD19+/20+ cells in
ascites by FCM analyses. c
Three hours after infusion,
lymphoma cells (22.4%) were
present in ascites. d At 24 h,
double-positive cells completely
disappeared
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